Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
How Has The Neuroendocrine Carcinoma Market Growth Evolved From 2024 To 2025, And What’s Ahead?
The market size for neuroendocrine carcinoma has seen robust growth in the past few years. Projections suggest an increase from $1.63 billion in 2024 to $1.75 billion in 2025, with a compound annual growth rate (CAGR) of 7.4%. The substantial growth during the historical period could be linked to the advancement in the imaging sector, a higher occurrence of neuroendocrine tumors, escalating investments, rising governmental initiatives, and the growing demand for neuroendocrine tumor treatments.
In the forthcoming years, the market size for neuroendocrine carcinoma is predicted to experience notable expansion. It is projected to reach a valuation of $2.31 billion in 2029, with a Compound Annual Growth Rate (CAGR) of 7.2%. Several contributing factors to this estimated growth within the forecast period are the escalating prevalence of cancer, increased approval of products, heightened utilization of advanced diagnostic imaging techniques, the emergence of targeted treatments, and an enhanced rate of diagnosis and diverse treatment options. Predicted trends within this period include advancements in diagnostic technology, improved imaging methods, targeted treatment strategies, progressive management of neuroendocrine tumors, and the evolution of targeted treatments and immunotherapies.
Download a free sample to assess the report’s scope and structure:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21229&type=smp
What Are the Major Market Drivers Behind the Rising Adoption of Neuroendocrine Carcinoma Market?
The neuroendocrine carcinoma market is projected to see a surge due to the rise in targeted therapies. Such treatments are created with a specific objective to pinpoint and disrupt the molecular or genetic irregularities leading to diseases like cancer. Reasons for increasing demand for targeted therapies include their efficacy for specifically curating treatments for gene mutations, advancement in personalized healthcare, and enhanced patient results with limited side effects. Neuroendocrine carcinoma aids in creating targeted therapies specially adapted to the genetic and biochemical attributes of the tumor, thus increasing the precision and success of treatment. As per a report by the American Society of Gene & Cell Therapy (ASGCT), a professional organization based in the US, and Citeline, an American drug and device supplier, the number of gene therapies in Phase II had grown by 5 percent from 247 at the end of Q1 2023 to 260 by the closing of Q2. Therefore, the rise in targeted therapies contributes to the expansion of the neuroendocrine carcinoma market.
Which Key Market Segments Comprise the Neuroendocrine Carcinoma Market and Drive Its Revenue Growth?
The neuroendocrine carcinomamarket covered in this report is segmented –
1) By Type: Gastroenteropancreatic Neuroendocrine Tumors; Carcinoid Tumors; Pheochromocytoma; Medullary Thyroid Carcinoma
2) By Diagnostic Tools: Imaging; Biopsy; Serology
3) By Treatment: Chemotherapy; Radiotherapy; Surgery; Other Treatments
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Hospitals; Clinics; Oncology Centers; Ambulatory Surgery Centers
Subsegments:
1) By Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): Pancreatic Neuroendocrine Tumors (pNETs); Small Intestinal Neuroendocrine Tumors; Gastric Neuroendocrine Tumors; Colorectal Neuroendocrine Tumors
2) By Carcinoid Tumors: Pulmonary Carcinoid Tumors; Gastrointestinal Carcinoid Tumors
3) By Pheochromocytoma: Adrenal Pheochromocytoma; Extra-Adrenal Paraganglioma
4) By Medullary Thyroid Carcinoma: Sporadic Medullary Thyroid Carcinoma; Hereditary Medullary Thyroid Carcinoma (MEN2-Associated)
Request customized data on this market:
https://www.thebusinessresearchcompany.com/customise?id=21229&type=smp
Which Areas Are Leading Regions in the Neuroendocrine Carcinoma Market Expansion Across the Globe?
North America was the largest region in the neuroendocrine carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuroendocrine carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Are the Strategic Trends Steering theNeuroendocrine Carcinoma Market Direction?
The bulk of companies operating within the neuroendocrine carcinoma market have shifted their focus towards creating improved therapy methods like targeted radiopharmaceutical therapy, in a bid to enhance treatment accuracy and the survival rate of patients. This therapy revolves around the use of radioactive molecules that specifically focus on delivering radiation to cancer stricken cells, while reducing damages to healthy tissues. To illustrate, Abdera Therapeutics Inc. – a biotech firm from Canada, was granted FDA-approved orphan drug designation for ABD-147, a targeted therapy for treating neuroendocrine carcinoma in September 2024. This is aimed at isolating tumors that express the DLL3 protein, a common characteristic in malignant neuroendocrine cancers such as small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). This FDA designation comes with several developmental perks including tax relief for clinical trials and the chance for market exclusivity, solidifying ABD-147’s position as a hopeful solution in this specific oncology market niche.
View the full report here:
https://www.thebusinessresearchcompany.com/report/neuroendocrine-carcinoma-global-market-report
How Is the Neuroendocrine Carcinoma Market Conceptually Defined?
Neuroendocrine carcinoma (NEC) refers to a rare and aggressive type of cancer that originates in neuroendocrine cells, which have traits of both nerve cells and hormone-producing cells. They are used for identifying and treating tumors that can develop in various organs, including the lungs, pancreas, and gastrointestinal tract, often requiring a combination of surgery, chemotherapy, and targeted therapies.
Purchase the full report and get a swift delivery:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21229
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Europe +44 7882 955267
Asia & Others +44 7882 955267 & +91 8897263534
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
